Ramanathan Rahul, Lee Joon Y, Dalton Jonathan F, Lin Ryan T, Lee Isaac, Gonzalez Christopher, Shaw Jeremy D, Schroeder Gregory D, Kepler Christopher K, Spitnale Michael, Vaccaro Alexander R, Gabrielli Alexandra S, Wawrose Richard A
Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
The Orland Bethel Family MSK Research Center (BMRC), Pittsburgh, Pennsylvania.
J Bone Joint Surg Am. 2025 Jul 10;107(16):1879-1886. doi: 10.2106/JBJS.24.01287.
➢ Glucagon-like peptide-1 (GLP-1) receptor agonists are a promising tool for preoperative weight loss in the patient who is undergoing orthopaedic surgery and has concomitant obesity and type-2 diabetes mellitus.➢ With regard to the perioperative management of GLP-1 receptor agonists for the orthopaedic surgeon, the American Society of Anesthesiologists (ASA) recommends withholding daily-dose GLP-1 therapy on the day of the elective surgical procedure and withholding weekly-dose therapy for the week prior to the procedure.➢ The ASA recommends postponing surgery or proceeding with "full stomach precautions" if the patient undergoing an orthopaedic procedure and taking GLP-1 therapy exhibits gastrointestinal symptoms on the day of the elective procedure.➢ In the trauma setting, patients taking GLP-1 therapy should proceed with the surgical procedure at the discretion of the surgeon with full stomach precautions or a preoperative point-of-care gastric ultrasound.➢ GLP-1 receptor agonists show the potential for disease modification in osteoarthritis and osteoporosis.
➢ 胰高血糖素样肽-1(GLP-1)受体激动剂是一种很有前景的工具,可用于接受骨科手术且伴有肥胖症和2型糖尿病的患者术前减重。
➢ 关于骨科医生对GLP-1受体激动剂的围手术期管理,美国麻醉医师协会(ASA)建议在择期手术当天停用每日剂量的GLP-1治疗,并在手术前一周停用每周剂量的治疗。
➢ ASA建议,如果接受骨科手术并正在接受GLP-1治疗的患者在择期手术当天出现胃肠道症状,则推迟手术或采取“饱胃预防措施”。
➢ 在创伤情况下,接受GLP-1治疗的患者应根据外科医生的判断进行手术,采取饱胃预防措施或术前即时胃超声检查。
➢ GLP-1受体激动剂在骨关节炎和骨质疏松症中显示出疾病改善的潜力。